

## **CRITICAL OUTCOME TECHNOLOGIES SELECTED TO PRESENT AT MULTIPLE INVESTOR CONFERENCES IN NEW YORK CITY**

**London, Ontario (May 27th, 2014):** Critical Outcome Technologies Inc. (“COTI” or the “Company”) (TSX-V: COT), the bioinformatics and accelerated drug discovery company, will be a featured presenter at two upcoming microcap investor conferences in New York City. The Company will also be presenting at a dinner being held by the Financial Investment Analysts of New York on the evening of May 27<sup>th</sup>. In addition to providing a Company overview at all three events, President and CEO Dr. Wayne Danter’s presentation will highlight the Company’s lead cancer drug candidate, COTI-2, the opportunity to do R&D collaborations with CHEMSAS®, and CHEMFirm, the Company’s small molecule profiling and investment due diligence tool.

On Wednesday, May 28<sup>th</sup>, Dr. Danter will present at SeeThruEquity’s Microcap Investor Conference being held at Convene Grand Central in Manhattan. Dr. Danter’s presentation is scheduled to begin at 2:30 p.m. EDT.

On Thursday, May 29<sup>th</sup>, Dr. Danter will present at the third annual Marcum Microcap Conference being held at the Grand Hyatt Hotel in Manhattan. Dr. Danter’s presentation is scheduled to begin at 10:00 a.m. EDT and will be available via a live webcast. To access the webcast, go to <http://wsw.com/webcast/marcum2/cot.v>.

“These important presentations provide the Company with multiple high impact opportunities to continue raising our profile with more potential life science investors and customers in the United States,” commented Dr. Danter.

Dr. Danter will also be participating in one-on-one meetings with potential investors and customers, and other interested parties who are registered to attend these conferences.

### **About Critical Outcome Technologies Inc.**

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules – dramatically reducing the time and cost to bring new drugs to market. COTI’S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit [www.criticaloutcome.com](http://www.criticaloutcome.com) or contact:

Critical Outcome Technologies Inc.

Dr. Wayne Danter

President & CEO

Tel: 519-858-5157

Email: [wdanter@criticaloutcome.com](mailto:wdanter@criticaloutcome.com)

Heisler Communications

Trevor Heisler

Investor Relations

Tel: 416-500-8061

Email: [trevor@heislercommunications.com](mailto:trevor@heislercommunications.com)

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*